Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Los Angeles, CA, March 05, 2026 (GLOBE NEWSWIRE) -- ANEUVO, a medical technology company advancing non-invasive neuromodulation for people living with spinal cord injury, today announced the closing...
-
VANCOUVER, British Columbia, March 04, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing...
-
VANCOUVER, British Columbia, Feb. 18, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing...
-
VANCOUVER, British Columbia, Feb. 12, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing...
-
Los Angeles, CA, Feb. 11, 2026 (GLOBE NEWSWIRE) -- ANEUVO (Niche Biomedical, Inc. d.b.a. ANEUVO), a medical technology company advancing non-invasive neuromodulation for people living with spinal...
-
NervGen Pharma to Present at Unite2Fight Paralysis’ 20th Annual Science and Advocacy Symposium
-
NervGen Pharma Appoints Adam Rogers as Chief Executive Officer to Continue Leading the Company’s Growth and Execution of Its Mission in Spinal Cord Injury
-
Empower BP is a landmark global pivotal study evaluating the safety and effectiveness of the implantable ARC-IM® System to address blood pressure instability after spinal cord injury (SCI)Blood...
-
NervGen Pharma today announced that the Company will ring the closing bell at the Nasdaq Stock Market on Thursday, January 22, 2026 in New York City
-
NervGen Pharma's common shares have been approved for listing on Nasdaq and will begin trading today, under the symbol "NGEN"